Literature DB >> 7962480

Anadamide, an endogenous cannabinoid receptor agonist inhibits lymphocyte proliferation and induces apoptosis.

H Schwarz1, F J Blanco, M Lotz.   

Abstract

This study examined the immunoregulatory effects of anadamide, the recently identified first endogenous cannabinoid receptor ligand. Anadamide caused dose-dependent inhibition of mitogen-induced T and B lymphocyte proliferation. Its potency was 3- and 10-fold less than that of the synthetic cannabinoids delta 8-tetrahydrocannabinol (delta 8-THC) and CP55940, respectively. Anadamide effects on DNA synthesis in T and B lymphocytes occurred rapidly as exposure of the cells during the final 4 h of culture was sufficient to achieve > 40% inhibition. Low doses of anadamide which caused significant inhibition of lymphocyte proliferation caused DNA fragmentation as demonstrated by immunohistochemistry, FACS analysis and Southern blotting. Apoptosis was also induced by high concentrations of delta 8-THC, but not by CP55940. Brain and peripheral cannabinoid receptor mRNA was expressed in PBMC with varying levels between individual donors. In summary, these findings demonstrate immunosuppressive effects of anadamide which are associated with inhibition of lymphocyte proliferation and the induction of cell death by apoptosis.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7962480     DOI: 10.1016/0165-5728(94)90152-x

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  39 in total

1.  Alcohol Versus Cannabinoids: A Review of Their Opposite Neuro-Immunomodulatory Effects and Future Therapeutic Potentials.

Authors:  Madhavan P Nair; Gloria Figueroa; Gianna Casteleiro; Karla Muñoz; Marisela Agudelo
Journal:  J Alcohol Drug Depend       Date:  2015-01-23

Review 2.  Effects of Cannabinoids on T-cell Function and Resistance to Infection.

Authors:  Toby K Eisenstein; Joseph J Meissler
Journal:  J Neuroimmune Pharmacol       Date:  2015-04-16       Impact factor: 4.147

Review 3.  Endocannabinoids and immune regulation.

Authors:  Rupal Pandey; Khalida Mousawy; Mitzi Nagarkatti; Prakash Nagarkatti
Journal:  Pharmacol Res       Date:  2009-04-07       Impact factor: 7.658

Review 4.  Endocannabinoid signalling in innate and adaptive immunity.

Authors:  Valerio Chiurchiù; Luca Battistini; Mauro Maccarrone
Journal:  Immunology       Date:  2015-03       Impact factor: 7.397

Review 5.  Lipid analogues as potential drugs for the regulation of mitochondrial cell death.

Authors:  Michael Murray; Herryawan Ryadi Eziwar Dyari; Sarah E Allison; Tristan Rawling
Journal:  Br J Pharmacol       Date:  2014-04       Impact factor: 8.739

6.  The CB1 cannabinoid receptor is coupled to the activation of protein kinase B/Akt.

Authors:  T Gómez del Pulgar ; G Velasco; M Guzmán
Journal:  Biochem J       Date:  2000-04-15       Impact factor: 3.857

Review 7.  Targeting astrocytomas and invading immune cells with cannabinoids: a promising therapeutic avenue.

Authors:  Eiron Cudaback; Nephi Stella
Journal:  Mol Neurobiol       Date:  2007-07-03       Impact factor: 5.590

Review 8.  Cannabinoid receptor 2: potential role in immunomodulation and neuroinflammation.

Authors:  Slava Rom; Yuri Persidsky
Journal:  J Neuroimmune Pharmacol       Date:  2013-03-08       Impact factor: 4.147

Review 9.  Cannabinoid-induced apoptosis in immune cells as a pathway to immunosuppression.

Authors:  Sadiye Amcaoglu Rieder; Ashok Chauhan; Ugra Singh; Mitzi Nagarkatti; Prakash Nagarkatti
Journal:  Immunobiology       Date:  2009-05-20       Impact factor: 3.144

10.  Anandamide suppresses proliferation and cytokine release from primary human T-lymphocytes mainly via CB2 receptors.

Authors:  Maria Teresa Cencioni; Valerio Chiurchiù; Giuseppina Catanzaro; Giovanna Borsellino; Giorgio Bernardi; Luca Battistini; Mauro Maccarrone
Journal:  PLoS One       Date:  2010-01-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.